We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 22, 2021

Maintenance Olaparib Does Not Adversely Impact Patient-Centered Outcomes in Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Patient-Centred Outcomes and Effect of Disease Progression on Health Status in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Receiving Maintenance Olaparib or Placebo (SOLO1): A Randomised, Phase 3 Trial
Lancet Oncol 2021 Apr 13;[EPub Ahead of Print], M Friedlander, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, A Lisyanskaya, GS Sonke, C Gourley, S Banerjee, A Oza, A González-Martín, C Aghajanian, WH Bradley, J Liu, C Mathews, F Selle, A Lortholary, ES Lowe, R Hettle, E Flood, E Parkhomenko, P DiSilvestro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading